FDA Grants Sacituzumab Govitecan Priority Review for Triple-Negative Breast Cancer

July 18, 2018 – The FDA has granted a priority review designation to a biologics license application (BLA) for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) following at least 2 prior therapies for metastatic disease, according to Immunomedics, the manufacturer of the antibody-drug conjugate. In phase II results presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), sacituzumab govitecan … (leggi tutto)